New pill aims to fight daytime sleepiness and sudden muscle collapse
NCT ID NCT07455383
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This phase 3 trial tests whether a daily tablet called ALKS 2680 can reduce daytime sleepiness and cataplexy (sudden muscle weakness) in 150 adults with narcolepsy type 1. Participants will take the drug or a placebo for 12 weeks, and researchers will measure changes in sleep tests and symptom reports.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ALKS 2680 (alixorexton) tablets
What this could lead to
If successful, this could provide a new daily medication to better control sleepiness and sudden muscle weakness in people with narcolepsy type 1.
What could go wrong
This is still an experimental drug; it may not work better than a placebo, and side effects are possible. The trial is relatively small (150 people) and lasts only 12 weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NARCOLEPSY TYPE 1 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Alkermes Investigational Site
RECRUITINGLos Angeles, California, 90025, United States
-
Alkermes Investigational Site
RECRUITINGBoulder, Colorado, 80301, United States
-
Alkermes Investigational Site
RECRUITINGBrandon, Florida, 33511, United States
-
Alkermes Investigational Site
RECRUITINGMiami, Florida, 33176, United States
-
Alkermes Investigational Site
RECRUITINGWinter Park, Florida, 32789, United States
-
Alkermes Investigational Site
RECRUITINGMacon, Georgia, 31210, United States
-
Alkermes Investigational Site
RECRUITINGNewton, Massachusetts, 02459, United States
-
Alkermes Investigational Site
RECRUITINGLansing, Michigan, 48911, United States
-
Alkermes Investigational Site
RECRUITINGSt Louis, Missouri, 63123, United States
-
Alkermes Investigational Site
RECRUITINGCincinnati, Ohio, 45245, United States
-
Alkermes Investigational Site
RECRUITINGWyomissing, Pennsylvania, 19610, United States
-
Alkermes Investigational Site
RECRUITINGColumbia, South Carolina, 29201, United States
-
Alkermes Investigational Site
RECRUITINGAustin, Texas, 78731, United States
-
Alkermes Investigational Site
RECRUITINGSan Antonio, Texas, 78229, United States
-
Alkermes Investigational Site
RECRUITINGSugar Land, Texas, 77478, United States
-
Alkermes Investigational Site
RECRUITINGMarkham, Ontario, L3R 1A3, Canada
-
Alkermes Investigational Site
RECRUITINGToronto, Ontario, M5S 3A3, Canada